MedTrace Logo

Comparative Study of Patterns of Immune Response to COVID 19 Vaccination

NCT05408299 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2022-06-07

No results posted yet for this study

Summary

An effective vaccine stands as the most effective way for controlling the COVID 19 pandemic , yet, immunogenic vaccine efficacy needs to be extensively studied . T cell responses against the structural proteins have been found to be the most immunogenic in peripheral blood mononuclear cells of convalescent SARS-CoV1 patients which needs to be tested in SARS -COV2 vaccine efficacy studies alongside with the sustainability of humoral and cellular immune responses . Clinically , immunocompromised patients face drastic outcome of infections , which led the Advisory Committee on Immunization Practices (ACIP) - USA -and the Joint Committee on Vaccination and Immunisation (JCVI) -UK- recommend COVID-19 vaccination of immunocompromised , the WHO Strategic Advisory Group of Experts on Immunization (SAGE), recommended that the three vaccines(Pfizer ,Moderna and Astra Zeneca) can be used for individuals with high-risk comorbidities . Nevertheless, there is an unmet research need concerning the immune response towards COVID 19 vaccination in this population .

Based on the previous work of our team in designing B and T cell epitopes distributed over the S protein , we will study the immune response in the available vaccines in Egypt.

Conditions

  • Immune Response to Covid 19 Vaccination

Interventions

BIOLOGICAL

Covid vaccines (Moderna - Pfizer- Astra Zeneca- Johnson and Johnson - Sinopahrm)

Vaccination

Sponsors & Collaborators

  • The holding company for biological products and vaccines (VACSERA)

    collaborator UNKNOWN

  • Theodor Bilharz Research Institute

    collaborator OTHER

  • National Research Centre, Egypt

    lead OTHER

Principal Investigators

  • Mohamed A Mokhles, Professor · National Research Center .

Eligibility

Min Age
15 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-20
Primary Completion
2023-02-28
Completion
2023-03-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05408299 on ClinicalTrials.gov